FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck Acquires 250,000 Shares

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck bought 250,000 shares of FibroGen stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $0.35 per share, for a total transaction of $87,500.00. Following the acquisition, the director now directly owns 323,722 shares in the company, valued at approximately $113,302.70. This trade represents a 339.11 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

FibroGen Price Performance

Shares of NASDAQ:FGEN opened at $0.34 on Wednesday. The business has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.43. The company has a market capitalization of $34.57 million, a PE ratio of -0.28 and a beta of 0.82. FibroGen, Inc. has a 1-year low of $0.18 and a 1-year high of $2.79.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $24.91 million. On average, sell-side analysts anticipate that FibroGen, Inc. will post -0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on FGEN. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of FibroGen in a research report on Tuesday, March 18th. StockNews.com started coverage on shares of FibroGen in a research note on Saturday. They set a “hold” rating on the stock.

Institutional Trading of FibroGen

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC raised its position in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the last quarter. Geode Capital Management LLC boosted its holdings in FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the last quarter. JPMorgan Chase & Co. grew its position in FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares during the period. Franklin Street Advisors Inc. NC raised its stake in FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of FibroGen by 80.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 605,572 shares during the period. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.